Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer

European Urology

Volumn 65, Issue 1, 2014, Pages 218-226

  Bertz, Simone ^a   Otto, Wolfgang ^b   Denzinger, Stefan ^b   Wieland, Wolf F ^b   Burger, Maximilian ^c   Stöhr, Robert ^a   Link, Stefan ^b   Hofstädter, Ferdinand ^b   Hartmann, Arndt ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Disease progression; Immunohistochemistry; pT1 bladder cancer; Recurrence; Risk assessment; Urinary bladder carcinoma

Indexed keywords

CYTOKERATIN 20; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CARCINOMA IN SITU; CYSTECTOMY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; BIOSYNTHESIS; BLADDER TUMOR; CANCER STAGING; CHEMISTRY; DISEASE COURSE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84888817951     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.05.033     Document Type: Article

References (31)

1. J. Ferlay, G. Randi, and C. Bosetti Declining mortality from bladder cancer in Europe BJU Int 101 2008 11 19
2. P.J. Goebell, and M.A. Knowles Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium Urol Oncol 28 2010 409 428
3. O. Shahin, G.N. Thalmann, C. Rentsch, L. Mazzucchelli, and U.E. Studer A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival J Urol 169 2003 96 100 discussion 100
4. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2008 303 314
5. S. Denzinger, H.M. Fritsche, W. Otto, A. Blana, W.F. Wieland, and M. Burger Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53 2008 146 152
6. R. Gonzalez-Campora, G. Davalos-Casanova, and A. Beato-Moreno Apoptotic and proliferation indexes in primary superficial bladder tumors Cancer Lett 242 2006 266 272
7. S. Desai, S.D. Lim, and R.E. Jimenez Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia Mod Pathol 13 2000 1315 1323
8. J. Southgate, P. Harnden, and L.K. Trejdosiewicz Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications Histol Histopathol 14 1999 657 664
9. P. Harnden, N. Mahmood, and J. Southgate Expression of cytokeratin 20 redefines urothelial papillomas of the bladder Lancet 353 1999 974 977
10. J.M. van Oers, P.J. Wild, and M. Burger FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours Eur Urol 52 2007 760 768
11. C. Wittekind, and H.J. Meyer TNM classification of malignant tumours ed. 7. 2010 Wiley-Blackwell Weinheim, Germany p. 246-9
12. Tumours of the urinary system L. Eble, G. Sauter, J.I. Epstein, and I.A. Sesterhenn World Health Organization classification of tumours - pathology and genetics of tumours of the urinary system and male genital organs 2004 IARC Press Lyon, France
13. M. Burger, S. Denzinger, and A. Hartmann Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade Br J Cancer 96 2007 1711 1715
14. D. Ramos, S. Navarro, R. Villamón, M. Gil-Salom, and A. Llombart-Bosch Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder Cancer 97 2003 1876 1883
15. D. Esrig, D. Elmajian, and S. Groshen Accumulation of nuclear p53 and tumor progression in bladder cancer N Engl J Med 331 1994 1259 1264
16. L.A. Kiemeney, J.A. Witjes, A.L. Verbeek, R.P. Heijbroek, and F.M. Debruyne The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group Br J Cancer 67 1993 806 812
17. H.W. Herr Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome Br J Urol 80 1997 762 765
18. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
19. L.A. Kiemeney, J.A. Witjes, R.P. Heijbroek, A.L. Verbeek, and F.M. Debruyne Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer J Urol 150 1993 60 64
20. A.A. Van Tilborg, C.H. Bangma, and E.C. Zwarthoff Bladder cancer biomarkers and their role in surveillance and screening Int J Urol 16 2009 23 30
21. A. Lopez-Beltran, R.J. Luque, and J. Alvarez-Kindelan Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters Am J Clin Pathol 122 2004 444 452
22. A. Quintero, J. Alvarez-Kindelan, and R.J. Luque Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder J Clin Pathol 59 2006 83 88
23. S. Krüger, C. Thorns, W. Stöcker, E. Müller-Kunert, A. Böhle, and A.C. Feller Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder Eur Urol 43 2003 138 145
24. B.W. van Rhijn, A.N. Vis, and T.H. van der Kwast Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome J Clin Oncol 21 2003 1912 1921
25. B.W. van Rhijn, T.C. Zuiverloon, and A.N. Vis Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer Eur Urol 58 2010 433 441
26. T.H. van der Kwast, and B. Bapat Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling Curr Opin Urol 19 2009 516 521
27. E. López-Knowles, S. Hernández, and M. Kogevinas The p53 pathway and outcome among patients with T1G3 bladder tumors Clin Cancer Res 12 2006 6029 6036
28. N. Malats, A. Bustos, and C.M. Nascimento P53 as a prognostic marker for bladder cancer: a meta-analysis and review Lancet Oncol 6 2005 678 686
29. P. Harnden, A. Allam, A.D. Joyce, A. Patel, P. Selby, and J. Southgate Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease Histopathology 27 1995 169 174
30. A. Klein, R. Zemer, V. Buchumensky, R. Klaper, and I. Nissenkorn Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma Cancer 82 1998 349 354
31. F. Barbisan, A. Santinelli, and R. Mazzucchelli Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur Cancer 112 2008 636 644